SG11201900738YA - Gpr156 variants and uses thereof - Google Patents
Gpr156 variants and uses thereofInfo
- Publication number
- SG11201900738YA SG11201900738YA SG11201900738YA SG11201900738YA SG11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gpr156
- aspartic acid
- pct
- protein
- Prior art date
Links
- 101150071692 Gpr156 gene Proteins 0.000 title 1
- 101001039301 Homo sapiens Probable G-protein coupled receptor 156 Proteins 0.000 abstract 4
- 102100041015 Probable G-protein coupled receptor 156 Human genes 0.000 abstract 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
- 235000003704 aspartic acid Nutrition 0.000 abstract 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000003104 endogenous depression Diseases 0.000 abstract 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101100505306 Homo sapiens GPR156 gene Proteins 0.000 abstract 1
- -1 cDNA Chemical class 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367973P | 2016-07-28 | 2016-07-28 | |
| PCT/US2017/044321 WO2018022967A1 (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900738YA true SG11201900738YA (en) | 2019-02-27 |
Family
ID=59649989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900738YA SG11201900738YA (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10266582B2 (ko) |
| EP (2) | EP4230648A3 (ko) |
| JP (2) | JP2019527229A (ko) |
| KR (2) | KR20240027874A (ko) |
| CN (1) | CN109563516B (ko) |
| AU (1) | AU2017302611B2 (ko) |
| CA (1) | CA3032124A1 (ko) |
| DK (1) | DK3491014T3 (ko) |
| IL (1) | IL264473A (ko) |
| MX (1) | MX2019001084A (ko) |
| SG (1) | SG11201900738YA (ko) |
| WO (1) | WO2018022967A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019527229A (ja) * | 2016-07-28 | 2019-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｐｒ１５６変異体及びその使用 |
| MX2020002643A (es) | 2017-09-06 | 2020-09-25 | Regeneron Pharma | Variantes relacionadas con el receptor de inmunoglobulina interleucina 1 simple (sigirr) y usos de estas. |
| US11470828B2 (en) * | 2019-01-17 | 2022-10-18 | Regeneran Pharmaceuticals, Inc. | Rodent model of mood disorders |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| ATE196313T1 (de) | 1993-06-04 | 2000-09-15 | Us Health | Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| WO1996005298A1 (en) | 1994-08-09 | 1996-02-22 | Ciba-Geigy Ag | Antitumor antisense oligonucleotides |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| AU7286696A (en) | 1995-10-13 | 1997-05-07 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| KR19990071523A (ko) | 1995-11-21 | 1999-09-27 | 해리 에이. 루스제 | Il－8 및 il－8 수용체에 대한 안티센스올리고누클레오티드에 의한 종양 성장의 억제방법 |
| CA2246503A1 (en) | 1996-02-15 | 1997-08-21 | National Institutes Of Health | Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
| CA2248762A1 (en) | 1997-10-22 | 1999-04-22 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of tnf-.alpha. |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| WO2001004137A1 (en) * | 1999-07-09 | 2001-01-18 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| AU2001255397A1 (en) * | 2000-04-18 | 2001-10-30 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ugt1a1 gene |
| AU2003300776A1 (en) | 2002-09-09 | 2004-05-25 | Omeros Corporation | G protein coupled receptors and uses thereof |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| CA2564501A1 (en) * | 2004-04-29 | 2005-11-24 | Merck Sharp & Dohme Limited | Azetidine glycine transporter inhibitors |
| WO2008061209A2 (en) | 2006-11-15 | 2008-05-22 | Omeros Corporation | G protein coupled receptors and uses thereof |
| AU2013262709A1 (en) * | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| DK3401400T3 (da) | 2012-05-25 | 2019-06-03 | Univ California | Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering |
| JP6620018B2 (ja) | 2012-12-06 | 2019-12-11 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ | Ｃｒｉｓｐｒに基づくゲノム修飾および制御 |
| JP2019527229A (ja) | 2016-07-28 | 2019-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｐｒ１５６変異体及びその使用 |
-
2017
- 2017-07-28 JP JP2019504021A patent/JP2019527229A/ja active Pending
- 2017-07-28 SG SG11201900738YA patent/SG11201900738YA/en unknown
- 2017-07-28 WO PCT/US2017/044321 patent/WO2018022967A1/en unknown
- 2017-07-28 US US15/662,689 patent/US10266582B2/en active Active
- 2017-07-28 DK DK17754224.8T patent/DK3491014T3/da active
- 2017-07-28 KR KR1020247005755A patent/KR20240027874A/ko not_active Application Discontinuation
- 2017-07-28 AU AU2017302611A patent/AU2017302611B2/en active Active
- 2017-07-28 EP EP23162215.0A patent/EP4230648A3/en active Pending
- 2017-07-28 EP EP17754224.8A patent/EP3491014B1/en active Active
- 2017-07-28 CA CA3032124A patent/CA3032124A1/en active Pending
- 2017-07-28 CN CN201780048589.4A patent/CN109563516B/zh active Active
- 2017-07-28 KR KR1020197001965A patent/KR102661616B1/ko active IP Right Grant
- 2017-07-28 MX MX2019001084A patent/MX2019001084A/es unknown
-
2019
- 2019-01-27 IL IL264473A patent/IL264473A/en unknown
- 2019-03-15 US US16/354,563 patent/US10562953B2/en active Active
-
2020
- 2020-01-03 US US16/733,663 patent/US11155598B2/en active Active
-
2021
- 2021-09-23 US US17/483,047 patent/US20220073589A1/en active Pending
-
2023
- 2023-02-10 JP JP2023019464A patent/JP2023071704A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240027874A (ko) | 2024-03-04 |
| US20190202891A1 (en) | 2019-07-04 |
| AU2017302611A1 (en) | 2019-03-14 |
| US10266582B2 (en) | 2019-04-23 |
| US20220073589A1 (en) | 2022-03-10 |
| IL264473A (en) | 2019-02-28 |
| DK3491014T3 (da) | 2023-05-30 |
| CA3032124A1 (en) | 2018-02-01 |
| KR102661616B1 (ko) | 2024-04-30 |
| JP2023071704A (ja) | 2023-05-23 |
| CN109563516B (zh) | 2023-10-27 |
| WO2018022967A1 (en) | 2018-02-01 |
| AU2017302611B2 (en) | 2021-12-09 |
| MX2019001084A (es) | 2019-06-10 |
| EP4230648A2 (en) | 2023-08-23 |
| CN109563516A (zh) | 2019-04-02 |
| US20180030114A1 (en) | 2018-02-01 |
| EP4230648A3 (en) | 2023-10-18 |
| EP3491014B1 (en) | 2023-04-05 |
| US20200231651A1 (en) | 2020-07-23 |
| EP3491014A1 (en) | 2019-06-05 |
| KR20190034532A (ko) | 2019-04-02 |
| JP2019527229A (ja) | 2019-09-26 |
| US11155598B2 (en) | 2021-10-26 |
| US10562953B2 (en) | 2020-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809649WA (en) | Macromolecule analysis employing nucleic acid encoding | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201906735RA (en) | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201901790YA (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201407789RA (en) | Humanized non-human animals with restricted immunoglobulin heavy chain loci | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201807134RA (en) | Transposon system and methods of use | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201900573UA (en) | Methods of purifying fc-containing proteins |